Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc. is anticipated to experience significant revenue growth driven by its Signatera molecular residual disease testing, with recent quarters showing a notable increase of 21,500 volumes quarter-over-quarter, translating to a robust 54% year-over-year growth. The company has outlined plans to expand reimbursement coverage for Signatera across various cancer types, which is expected to enhance average selling prices, gross margins, and operating cash flow. Additionally, Natera's recent financial performance included an approximately $80 million revenue beat in the third quarter and an upward revision of its 2025 revenue guidance by $160 million, reflecting strong operational momentum.

Bears say

Natera anticipates continued margin erosion due to reductions in in-network pricing as it expands its total addressable market to incorporate more average-risk patients. The company faces significant risks from potential negative developments such as regulatory issues, reimbursement challenges, and delays in product launches, which could adversely impact its stock performance. Additionally, competition from firms like Guardant Health, which may struggle with reimbursement and adoption in emerging markets, presents further pressure on Natera's growth prospects in the diagnostic space.

Natera (NTRA) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 14 analysts, Natera (NTRA) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $253.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $253.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.